State Key Laboratory of Oral Diseases, National Clinical Research Center for Oral Diseases, West China School of Stomatology, Sichuan University, Chengdu, China.
Department of Pediatric Dentistry, West China School of Stomatology, Sichuan University, Chengdu, China.
Drug Deliv. 2021 Dec;28(1):272-284. doi: 10.1080/10717544.2021.1876182.
Head and neck cancer (HNC) is among the most common malignancy that has a profound impact on human health and life quality. The treatment for HNC, especially for the advanced cancer is stage-dependent and in need of combined therapies. Various forms of adjuvant treatments such as chemotherapy, phototherapy, hyperthermia, gene therapy have been included in the HNC therapy. However, there are still restrictions with traditional administration such as limited in situ therapeutic effect, systemic toxicity, drug resistance, etc. In recent years, stimuli-responsive drug delivery systems (DDSs) have attracted the great attention in HNC therapy. These intelligent DDSs could respond to unique tumor microenvironment, external triggers or dual/multi stimulus with more specific drug delivery and release, leading to enhanced treatment efficiency and less reduced side effects. In this article, recent studies on stimuli-responsive DDSs for HNC therapy were summarized, which could respond to endogenous and exogenous triggers including pH, matrix metalloproteinases (MMPs), reactive oxygen species (ROS), redox condition, light, magnetic field and multi stimuli. Their therapeutic remarks, current limits and future prospect for these intelligent DDSs were discussed. Furthermore, multifunctional stimuli-responsive DDSs have also been reviewed. With the modification of drug carriers or co-loading with therapeutic agents. Those intelligent DDSs showed more biofunctions such as combined therapeutic effects or integration of diagnosis and treatment for HNC. It is believed that stimuli-responsive drug delivery systems showed great potential for future clinic translation and application for the treatment of HNC.
头颈部癌症(HNC)是最常见的恶性肿瘤之一,对人类健康和生活质量有深远的影响。HNC 的治疗,尤其是晚期癌症,依赖于分期和联合治疗。各种辅助治疗形式,如化疗、光疗、热疗、基因治疗,已被纳入 HNC 的治疗中。然而,传统的给药方式仍存在局限,如局部治疗效果有限、全身毒性、耐药性等。近年来,刺激响应型药物传递系统(DDS)在 HNC 治疗中引起了广泛关注。这些智能 DDS 可以响应独特的肿瘤微环境、外部刺激或双/多刺激,实现更特异的药物传递和释放,从而提高治疗效果,减少副作用。本文总结了近年来用于 HNC 治疗的刺激响应型 DDS 的研究进展,这些 DDS 可以响应内源性和外源性刺激,包括 pH、基质金属蛋白酶(MMPs)、活性氧(ROS)、氧化还原状态、光、磁场和多刺激。讨论了这些智能 DDS 的治疗意义、当前的局限性和未来的前景。此外,还综述了多功能刺激响应型 DDS。通过对药物载体进行修饰或与治疗剂共载,这些智能 DDS 表现出更多的生物功能,如联合治疗效果或整合 HNC 的诊断和治疗。相信刺激响应型药物传递系统具有很大的临床转化和应用潜力,可用于治疗 HNC。